GET THE APP
Lymphoma News In Healthcare | Open Access Journals
Cancer Science & Therapy

Cancer Science & Therapy

ISSN: 1948-5956

Open Access
Spanish Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil
Submit Manuscript arrow_forward arrow_forward ..

Lymphoma News In Healthcare

Truxima is a brand-name prescription medication. It’s FDA-approved to treat certain forms of the following conditions in adults:Non-Hodgkin lymphoma. Truxima is used alone and with other drugs to treat different kinds of non-Hodgkin lymphoma (NHL):Truxima alone for B-cell NHL. The cancer must be a type called CD20-positive. It must also be low-grade (slow growing) or a kind known as follicular lymphoma (FL). In addition, the cancer must be relapsed (came back) or refractory (didn’t improve) after treatment. For this use, Truxima is used alone.Truxima with chemotherapy for B-cell NHL. The cancer must be CD20-positive, low-grade or FL, and it must not have been treated before. For this purpose, Truxima is used with chemotherapy. If you have a partial or complete response* to Truxima and chemotherapy, you may go on to use Truxima alone.Truxima after chemotherapy for B-cell NHL. The cancer must be low-grade and CD20-positive. Also, it must be non-progressing. This means that the cancer didn’t get worse after you tried chemotherapy with cyclophosphamide, vincristine, and prednisone (Rayos). For this purpose, you’ll use Truxima alone.Truxima with chemotherapy for diffuse large B-cell lymphoma. The diffuse large B-cell lymphoma (DLBCL) must be CD20-positive and must not have been treated before. For this purpose, Truxima is used with the drugs cyclophosphamide, doxorubicin, vincristine, and prednisone, or with other chemotherapy medications known as anthracyclines.

 

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

Awards & Nominations

50+ Million Readerbase

Journal Highlights

Google Scholar citation report
Citations: 5332

Cancer Science & Therapy received 5332 citations as per Google Scholar report

Citation image
Cancer Science & Therapy peer review process verified at publons
Publon image

Indexed In

Related Links

PMC/PubMed Indexed Articles
Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment
Advances in NKT cell Immunotherapy for Glioblastoma.

View More »

 

Open Access Journals

arrow_upward arrow_upward